Emergent BioSolutions Inc. has inked another deal with fellow Gaithersburg biotech Novavax Inc. — this time, for its seasonal flu vaccine. The agreement means Emergent (NYSE: EBS) will develop and manufacture NanoFlu, the influenza vaccine which Novavax (NASDAQ: NVAX) successfully pushed through phase 3 clinical trials in a critical win announced March 24. It also comes just a few weeks after the two companies teamed up to get a COVID-19 vaccine to the clinic in the race against the pandemic.…
from https://www.bizjournals.com/baltimore/news/2020/04/01/novavax-emergent-biosolutions-expand-partnership.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/614201728109297664
No comments:
Post a Comment